Related Experiment Video
Updated: Aug 17, 2026

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
Published on: March 25, 2020
[Selective cholesterol absorption inhibition as a new prospect in treatment of hypercholesterolemia]
Joan Lima1, Vicent Fonollosa, Pilar Chacón
1Unidad de Lípidos, Servicio de Medicina Interna, Hospital General Vall d'Hebron, 08035 Barcelona, España. joanlima@hgvhebron.es
Abstract:
Ezetimibe is the first of a new class of lipid-lowering drugs, the 2-azetidinones, which selectively inhibits the absorption of intestinal cholesterol. Ezetimibe's mechanism of action complements that of cholesterol synthesis inhibitors. Ezetimibe as monotherapy or in combination with statins significantly decreases plasma cLDL levels. As monotherapy, ezetimibe is well tolerated with a side-effect profile similar to placebo, whereas in combination with statins no differences in the incidence of myopathy, rhabdomyolysis or elevated liver enzymes are reported.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacogenomics: Identification of New Drug Targets
Cholesterol: Significance and Regulation
Considering cholesterol and...
Bioavailability Enhancement: Drug Permeability Enhancement
Lipid Digestion
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
